Bionano Genomics, Inc.
Tyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.
Bionano Genomics (BNGO) reported that three studies showed its optical genome mapping (OGM) technology identified high-risk genomic alterations in blood cancers, often missed by standard methods. OGM detected significant variants in 15.9% of MDS cases and 46% of cytogenetically normal AML samples, impacting survival rates. The studies suggest OGM could improve risk stratification and treatment planning. BNGO shares are up 2.05% at $1.24.
Bionano Genomics (BNGO) reported Q2 2026 revenue of $8.2 million, up 21% year over year, driven by higher OGM consumables sales. Flow cell sales rose 27% to 9,219 units, though the company said it is backordered due to manufacturing constraints. Installed base was 397 systems. Adjusted gross margin was 53%. Full-year 2026 revenue guidance is $31 million to $33 million.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning BNGO (Bionano Genomics, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent BNGO coverage spans financial news, earnings and technology.
In the last 30 days, BNGO insiders filed 2 SEC Form 4 transactions — 2 purchases ($10K) and no sales. The most active reporter was Luderer Albert, Interim Chief Executive, with 2 filings.
Study results validate technology, potentially expanding market adoption.
Positive validation of BNGO's OGM technology could boost demand and share price.
The call provides fresh guidance and operational constraints that directly affect near-term revenue timing and longer-term consumables growth.
Guidance raise plus a stated path to clear flow-cell constraints should improve near-term revenue visibility, but backlog and supply timing remain key risks.
The 8-K provides fresh quarterly datapoints plus explicit Q3 and full-year 2026 revenue guidance, which can reset near-term expectations.
AlphAI scores every news story that mentions BNGO with an AI model for sentiment and relevance, and aggregates insider trades from Bionano Genomics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.
3 min readBionano Genomics (BNGO) reported that three studies showed its optical genome mapping (OGM) technology identified high-risk genomic alterations in blood cancers, often missed by standard methods. OGM detected significant variants in 15.9% of MDS cases and 46% of cytogenetically normal AML samples, impacting survival rates. The studies suggest OGM could improve risk stratification and treatment planning. BNGO shares are up 2.05% at $1.24.
3 min readBionano Genomics (BNGO) reported Q2 2026 revenue of $8.2 million, up 21% year over year, driven by higher OGM consumables sales. Flow cell sales rose 27% to 9,219 units, though the company said it is backordered due to manufacturing constraints. Installed base was 397 systems. Adjusted gross margin was 53%. Full-year 2026 revenue guidance is $31 million to $33 million.
6 min readBionano Genomics reported Q2 2026 results on an earnings call, citing 30% YoY consumables growth and record 53% adjusted gross margin from higher adoption and efficiency. Full-year 2026 revenue guidance was raised to $31M-$33M. Flow-cell backorders and manufacturing constraints are expected to ease by Q4 2026. Software revenue fell 16% YoY.
7 min readBionano Genomics, Inc. (BNGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bionano Reports Second Quarter 2026 Results and Provides a Business Update Conference call today, August 10, 2026, at 4:30 PM ET SAN DIEGO, August 10, 2026 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarte
6 min readBionano Genomics (Nasdaq: BNGO) said 13 studies published in 2026 covering 730 samples across multiple countries evaluated optical genome mapping (OGM) for structural-variant detection in reproductive health and prenatal genetic disorders. The company cited results including 1-in-4 diagnoses in unexplained infertility (220 subjects) and up to 99.03% prenatal concordance (217 samples).
4 min readBionano Genomics director Kristiina Vuori, MD, was granted 9,149 stock options at an exercise price of $1.19 per share. These options, part of her compensation, will vest in equal monthly installments over 12 months or fully upon a Change of Control, and expire on May 13, 2036. This transaction is considered a neutral event in terms of filing impact and sentiment, as it represents equity compensation rather than an open-market purchase.
2 min readBionano Genomics, Inc. (BNGO) reported a Q1 loss of $0.76 per share, outperforming the Zacks Consensus Estimate of a $0.81 loss and surpassing year-ago revenues. The company posted revenues of $6.69 million for the quarter ended March 2026, beating estimates by 2.88%. Despite an underperforming stock year-to-date, its earnings outlook is favorable, earning it a Zacks Rank #2 (Buy).
3 min readBionano Genomics, Inc. (Nasdaq: BNGO) announced it will report its first quarter 2026 financial results and discuss recent corporate progress during a conference call and live webcast on Wednesday, May 13, 2026, at 4:30 p.m. Eastern Time. Interested parties can register for the event and a replay will be available on the company's investor relations website for at least 30 days.
2 min readH.C. Wainwright has lowered its price target for Bionano Genomics (NASDAQ:BNGO) to $6 from $7, while maintaining a Buy rating. This adjustment is primarily due to an increased share count, despite the stock trading near its 52-week low and an InvestingPro analysis suggesting it may be undervalued. Bionano Genomics reported a revenue decline for Q4 2025 and the full year 2025, but management provided 2026 revenue guidance indicating potential topline growth of up to 16%.
3 min read
